{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=76",
    "query": {
      "intervention": "Open Label Extension Study",
      "page": 76
    },
    "page_size": 10
  },
  "pagination": {
    "page": 76,
    "page_size": 10,
    "total_count": 2086,
    "total_pages": 209,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=77&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=75&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T21:08:44.305Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04432831",
      "title": "A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Faricimab",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1479,
      "start_date": "2020-08-05",
      "completion_date": "2023-10-11",
      "has_results": true,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-11-11T21:08:44.305Z",
      "location_count": 119,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 105 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04432831"
    },
    {
      "nct_id": "NCT05227209",
      "title": "A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Episodes, Bipolar I Depression"
      ],
      "interventions": [
        {
          "name": "SEP-4199 CR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 64,
      "start_date": "2022-03-17",
      "completion_date": "2023-11-17",
      "has_results": true,
      "last_update_posted_date": "2025-02-21",
      "last_synced_at": "2026-11-11T21:08:44.305Z",
      "location_count": 25,
      "location_summary": "Huntsville, Alabama • Anaheim, California • Imperial, California + 22 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Imperial",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05227209"
    },
    {
      "nct_id": "NCT02312687",
      "title": "Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "X-Linked Hypophosphatemia"
      ],
      "interventions": [
        {
          "name": "KRN23",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kyowa Kirin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20,
      "start_date": "2015-01-30",
      "completion_date": "2018-11-30",
      "has_results": true,
      "last_update_posted_date": "2024-05-06",
      "last_synced_at": "2026-11-11T21:08:44.305Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02312687"
    },
    {
      "nct_id": "NCT05968430",
      "title": "Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "lorundrostat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mineralys Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1076,
      "start_date": "2023-07-14",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-11T21:08:44.305Z",
      "location_count": 128,
      "location_summary": "Birmingham, Alabama • Foley, Alabama • Chandler, Arizona + 101 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05968430"
    },
    {
      "nct_id": "NCT06561321",
      "title": "Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Palmoplantar Keratoderma"
      ],
      "interventions": [
        {
          "name": "Tapinarof",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2024-10-30",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-11-11T21:08:44.305Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06561321"
    },
    {
      "nct_id": "NCT00171730",
      "title": "An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acromegaly"
      ],
      "interventions": [
        {
          "name": "Pasireotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "2004-08-24",
      "completion_date": "2013-12-06",
      "has_results": true,
      "last_update_posted_date": "2021-09-05",
      "last_synced_at": "2026-11-11T21:08:44.305Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Ann Arbor, Michigan • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00171730"
    },
    {
      "nct_id": "NCT03993392",
      "title": "SUBLOCADE Rapid Initiation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Opioid-use Disorder"
      ],
      "interventions": [
        {
          "name": "TM buprenorphine",
          "type": "DRUG"
        },
        {
          "name": "SUBLOCADE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indivior Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2019-08-29",
      "completion_date": "2019-12-26",
      "has_results": true,
      "last_update_posted_date": "2025-03-25",
      "last_synced_at": "2026-11-11T21:08:44.305Z",
      "location_count": 1,
      "location_summary": "Berlin, New Jersey",
      "locations": [
        {
          "city": "Berlin",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03993392"
    },
    {
      "nct_id": "NCT03488524",
      "title": "Open Label Extension Study of AMX0035 in Patients With ALS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis",
        "ALS"
      ],
      "interventions": [
        {
          "name": "AMX0035",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amylyx Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 90,
      "start_date": "2018-03-29",
      "completion_date": "2021-03-01",
      "has_results": true,
      "last_update_posted_date": "2025-08-13",
      "last_synced_at": "2026-11-11T21:08:44.305Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Orange, California • San Francisco, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03488524"
    },
    {
      "nct_id": "NCT04103450",
      "title": "Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Vibegron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Urovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "45 Years and older · Male only"
      },
      "enrollment_count": 276,
      "start_date": "2019-09-19",
      "completion_date": "2022-07-29",
      "has_results": true,
      "last_update_posted_date": "2024-08-21",
      "last_synced_at": "2026-11-11T21:08:44.305Z",
      "location_count": 31,
      "location_summary": "Huntsville, Alabama • Lincoln, California • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Lincoln",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04103450"
    },
    {
      "nct_id": "NCT05789524",
      "title": "The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia a",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "SerpinPC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ApcinteX Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2023-07-06",
      "completion_date": "2025-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-03-11",
      "last_synced_at": "2026-11-11T21:08:44.305Z",
      "location_count": 10,
      "location_summary": "Aurora, Colorado • Tampa, Florida • Indianapolis, Indiana + 7 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05789524"
    }
  ]
}